Branded Legacy, Inc. Signs Letter of Intent to Acquire a Mycology Research Lab
18 Julho 2023 - 10:05AM
InvestorsHub NewsWire
Company Executes Immediate Action
Plan
Melbourne, FL -- July 18, 2023 -- InvestorsHub NewsWire
-- Branded Legacy, Inc. (
OTC.PK:
BLEG), a holding company specializing in growth through
acquisitions with a focus on the Biotechnology sector, announced
today that is has a signed letter of intent to acquires
Mycoenlighten, a mycology research lab that specializes in alkaloid
extraction, purification, and synthesis.
Founded in 2023, MycoEnlighten is a pioneering mycology
research lab focused on exploring the capabilities of functional
mushroom blends. With established intellectual property, the
company has become a leading authority in the field, driving
innovation in the field of mycology. Through relentless research
and breakthrough discoveries, MycoEnlighten is dedicated to
developing advanced techniques for creating mushroom based medicine
using cutting-edge biotechnology and synthetic biology.
"We are excited to announce that we have initiated discussions
regarding potentially being acquired. This proactive step reflects
our enthusiasm for exploring new avenues of growth and expanding
our company's portfolio, setting the stage for an exciting future
ahead." says Brandon Arndt from MycoEnlighten.
The Company's CEO, David Oswald, has put together an exciting
strategic plan that is already in motion. This comprehensive
strategy includes targeted acquisitions, diversified product
portfolios, and projected revenue growth, all aimed at driving the
company's expansion and delivering highly promising returns for its
valued investors.
According to Oswald, these growth vectors are at the core of
their strategic plan. He expresses his enthusiasm, stating, " We
are carrying out our strategy, which calls for targeted
acquisitions, a variety of product offerings, and anticipated
revenue growth. These approaches will support the growth of our
business and produce good results for our shareholders."
Branded Legacy expects significant advances in capabilities
and scale within the next 6-12 months. This includes enhancements
in co-packing; presence in tradeshows and industry publications;
teleconferences and interviews; and brand awareness with product
campaigns.
About MycoEnlighten:
Founded in 2023, Mycoenlighten began as a small mycology
research lab with a mission to explore the capabilities of
alkaloids. The company brings established IP to the table which
places Mycoenlighten as a prominent player in the field. Through
relentless research and breakthrough discoveries, Mycoenlighten is
emerging as a leading authority in mycology, paving the way for
innovative applications and advancements in alkaloid extraction and
future technologies.
MycoEnlighten is committed to pioneering future technologies in
mycology. The company is developing innovative techniques for
alkaloid extraction, purification, and synthesis to optimize their
effectiveness and maximize their potential applications. By
leveraging advancements in biotechnology, genomics, and synthetic
biology, they aim to unlock new pathways for the discovery and
production of valuable alkaloids.
Safe Harbor Statement:
The information posted in this release may contain
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. You can identify these
statements by the use of the words "may," "will," "should,"
"plans," "expects," "anticipates," "continue," "estimate,"
"project," "intend," and similar expressions. Forward-looking
statements involve risks and uncertainties that could cause actual
results to differ materially from those projected or anticipated.
These risks and uncertainties include, but are not limited to,
general economic and business conditions, effects of continued
geopolitical unrest and regional conflicts, competition, changes in
technology and methods of marketing, delays in completing various
engineering and manufacturing programs, changes in customer order
patterns, changes in product mix, continued success in
technological advances and delivering technological innovations,
shortages in components, production delays due to performance
quality issues with outsourced components, and various other
factors beyond the Company's control.
www.brandedlegacy.com
(321) 345-3565
info@brandedlegacy.com
Branded Legacy (PK) (USOTC:BLEG)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
Branded Legacy (PK) (USOTC:BLEG)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025
